What inspired you to pursue aging research?
Watching my grandfather decline in health during his last two decades. It taught me the difference between lifespan and healthspan before I knew the terms. I want to help create a future where rationally designed therapeutic interventions compress late-life morbidity to months instead of the years my grandfather experienced.
In your view, what does AFAR mean to the field, and what does it mean, for you, to receive an AFAR grant now?
AFAR embodies the idea that a fundamental understanding of aging biology will allow us to develop therapies that block specific, molecularly-defined aging processes that lead to disease. Support from AFAR shows that my work is valued by the field and the conference organized by AFAR will provide an opportunity to connect with others who have similar research interests.
What is exciting about your research’s potential impact?
Metformin has shown potential as a first-generation gerotherapeutic in humans. I’m most excited about the possibility that gaining a molecular understanding of metformin action will facilitate the development of improved interventions in the future.
How would you describe your research to a non-scientist?
I study a drug that has the potential to improve the health of older adults, not just treat a specific disease. By understanding how this drug works we as a field will have a clearer picture of what physiologic parameters need to be modulated to improve healthspan.
